Show simple item record

dc.contributor.authorBeeton, Michael L.
dc.contributor.authorAlves, D. R.
dc.contributor.authorEnright, M. C.
dc.contributor.authorJenkins, A. T. A.
dc.date.accessioned2016-03-02T12:17:08Z
dc.date.available2016-03-02T12:17:08Z
dc.date.issued2015
dc.identifier.citationBeeton M. L., Alves. D. R., Enright M. C. and Jenkins A. T. A. (2016) ' Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model', International Journal of Antimicrobial Agents, 46 (2), pp.196-200en_US
dc.identifier.issn0924-8579
dc.identifier.urihttp://hdl.handle.net/10369/7736
dc.descriptionThis article was published in International Journal of Antimicrobial Agents on 25th May 2015 (online), available at http://dx.doi.org/10.1016/j.ijantimicag.2015.04.005en_US
dc.description.abstractThe Galleria mellonella infection model was used to assess the in vivo efficacy of phage therapy against laboratory and clinical strains of Pseudomonas aeruginosa. In a first series of experiments, Galleria were infected with the laboratory strain P. aeruginosa PAO1 and were treated with varying multiplicity of infection (MOI) of phages either 2 h post-infection (treatment) or 2 h pre-infection (prevention) via injection into the haemolymph. To address the kinetics of infection, larvae were bled over a period of 24 h for quantification of bacteria and phages. Survival rates at 24 h when infected with 10 cells/larvae were greater in the prevention versus treatment model (47% vs. 40%, MOI = 10; 47% vs. 20%, MOI = 1; and 33% vs. 7%, MOI = 0.1). This pattern held true when 100 cells/larvae were used (87% vs. 20%, MOI = 10; 53% vs. 13%, MOI = 1; 67% vs. 7%, MOI = 0.1). By 24 h post-infection, phages kept bacterial cell numbers in the haemolymph 1000-fold lower than in the non-treated group. In a second series of experiments using clinical strains to further validate the prevention model, phages protected Galleria when infected with both a bacteraemia (0% vs. 85%) and a cystic fibrosis (80% vs. 100%) isolate. Therefore, this study validates the use of G. mellonella as a simple, robust and cost-effective model for initial in vivo examination of P. aeruginosa-targeted phage therapy, which may be applied to other pathogens with similarly low infective doses.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesInternational Journal of Antimicrobial Agents
dc.rightsCreative Commons Attribution Non-Commercial No Derivatives License
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subjectpseudomonas aeruginosaen_US
dc.subjectphage therapyen_US
dc.subjectgalleria mellonellaen_US
dc.subjectinfection modelen_US
dc.titleAssessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection modelen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1016/j.ijantimicag.2015.04.005
dc.date.dateAccepted2015-04-15


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Creative Commons Attribution Non-Commercial No Derivatives License
Except where otherwise noted, this item's license is described as Creative Commons Attribution Non-Commercial No Derivatives License